A Systematic Evaluation of the Dosing Regimens for Approved Targeted Therapies and Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma From a Project OPTIMUS Perspective

Documenti analoghi

• Disentangling Anti‐Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab
  di: Aymara Sancho‐Araiz, et al.
  Pubblicazione: (2024)
• Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions. Authors' reply
  di: L. Aceituno, et al.
  Pubblicazione: (2026)
• Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions
  di: Mohammad Saeid Rezaee‐Zavareh, et al.
  Pubblicazione: (2026)
• A Consideration of Exploratory Approaches to Comedications Associated With Immune‐Related Adverse Events during Immune Checkpoint Inhibitor Therapy
  di: Yoshihiro Noguchi, et al.
  Pubblicazione: (2025)
• A Comparative Clinical Pharmacology Analysis of FDA‐Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology
  di: Huy X. Ngo, et al.
  Pubblicazione: (2024)